MannKind Corporation
Clinical trials sponsored by MannKind Corporation, explained in plain language.
Biopharmaceutical company known for inhaled insulin products.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New inhaled insulin combo aims to simplify diabetes care for teens Results expected Mar 2027 (estimated)
-
New inhaled insulin combo aims to simplify diabetes care for teens
Disease control Recruiting nowThis study tests a new approach for teens (ages 10-17) recently diagnosed with type 1 diabetes. They will use an inhaled insulin called Afrezza along with a long-acting injected insulin. The goal is to see if this combination helps keep blood sugar in a healthy range and is safe …
Phase 2 • Sponsor: Mannkind Corporation • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Inhaled drug could offer new hope for lung scarring disease
Disease control Recruiting nowThis phase 2 trial tests whether an inhaled form of nintedanib (MNKD-201) is safe and effective for people with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring. About 210 adults with IPF will receive either a low or high dose of the inhaled drug or a plac…
Phase 2 • Sponsor: Mannkind Corporation • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC